IGFBP2 and cancer: In BRAFV600 mutant cancer cells, the haploinsufficiency of histone deacetylase Sirtuinb 6 (SIRT6) allowed BRAFV600-mutant melanoma cell persistence in the presence of MAPK inhibitors due to upregulating insulin like growth factor binding protein 2 (IGFBP2) expression via increasing chromatin accessibility at the IGFBP2 locus (173).